WallStSmart

Abbott Laboratories (ABT)vsVertiv Holdings Co (VRT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 316% more annual revenue ($45.13B vs $10.84B). VRT leads profitability with a 14.4% profit margin vs 13.9%. ABT appears more attractively valued with a PEG of 1.29. VRT earns a higher WallStSmart Score of 67/100 (B-).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

VRT

Strong Buy

67

out of 100

Grade: B-

Growth: 10.0Profit: 8.0Value: 3.7Quality: 6.3
Piotroski: 4/9Altman Z: 2.25
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$87.55

Current Price

$84.35

$3.20 discount

UndervaluedFair: $87.55Overvalued

Intrinsic value data unavailable for VRT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

VRT4 strengths · Avg: 9.8/10
Return on EquityProfitability
45.1%10/10

Every $100 of equity generates 45 in profit

Revenue GrowthGrowth
30.1%10/10

Revenue surging 30.1% year-over-year

EPS GrowthGrowth
135.7%10/10

Earnings expanding 135.7% YoY

Market CapQuality
$130.60B9/10

Large-cap with strong market position

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

VRT3 concerns · Avg: 2.7/10
PEG RatioValuation
1.664/10

Expensive relative to growth rate

P/E RatioValuation
85.4x2/10

Premium valuation, high expectations priced in

Price/BookValuation
35.7x2/10

Trading at 35.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : VRT

The strongest argument for VRT centers on Return on Equity, Revenue Growth, EPS Growth. Revenue growth of 30.1% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : VRT

The primary concerns for VRT are PEG Ratio, P/E Ratio, Price/Book. A P/E of 85.4x leaves little room for execution misses.

Key Dynamics to Monitor

ABT profiles as a value stock while VRT is a growth play — different risk/reward profiles.

VRT carries more volatility with a beta of 2.10 — expect wider price swings.

VRT is growing revenue faster at 30.1% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

VRT scores higher overall (67/100 vs 56/100) and 30.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Vertiv Holdings Co

INDUSTRIALS · ELECTRICAL EQUIPMENT & PARTS · USA

Vertiv Holdings Co designs, manufactures and services critical digital infrastructure technologies and lifecycle services for data centers, communication networks, and commercial and industrial environments in the Americas, Asia Pacific, Europe, the Middle East, and Africa. The company is headquartered in Columbus, Ohio.

Want to dig deeper into these stocks?